Envestnet Asset Management Inc. Boosts Position in McKesson Corporation $MCK

Envestnet Asset Management Inc. boosted its stake in shares of McKesson Corporation (NYSE:MCK) by 12.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 330,647 shares of the company’s stock after buying an additional 36,451 shares during the quarter. Envestnet Asset Management Inc. owned approximately 0.27% of McKesson worth $255,438,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in McKesson by 2.0% in the second quarter. Vanguard Group Inc. now owns 12,072,090 shares of the company’s stock worth $8,846,186,000 after purchasing an additional 232,286 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of McKesson by 4.1% in the 2nd quarter. Geode Capital Management LLC now owns 2,820,724 shares of the company’s stock worth $2,057,065,000 after buying an additional 112,224 shares during the period. Alliancebernstein L.P. lifted its holdings in shares of McKesson by 150.4% in the 2nd quarter. Alliancebernstein L.P. now owns 2,268,015 shares of the company’s stock worth $1,661,956,000 after buying an additional 1,362,386 shares during the period. Norges Bank bought a new position in shares of McKesson during the 2nd quarter worth $1,346,661,000. Finally, Arrowstreet Capital Limited Partnership increased its stake in shares of McKesson by 56.4% during the second quarter. Arrowstreet Capital Limited Partnership now owns 1,236,536 shares of the company’s stock valued at $906,109,000 after buying an additional 446,060 shares during the period. 85.07% of the stock is currently owned by institutional investors.

McKesson Stock Up 16.7%

Shares of MCK opened at $959.34 on Friday. The company has a 50 day moving average of $827.03 and a two-hundred day moving average of $777.93. McKesson Corporation has a twelve month low of $570.51 and a twelve month high of $971.93. The company has a market cap of $118.41 billion, a price-to-earnings ratio of 27.59, a price-to-earnings-growth ratio of 1.35 and a beta of 0.40.

McKesson (NYSE:MCK) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, beating the consensus estimate of $9.19 by $0.15. The firm had revenue of $106.16 billion during the quarter, compared to analyst estimates of $105.98 billion. McKesson had a negative return on equity of 303.62% and a net margin of 1.09%.The business’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $8.03 EPS. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, sell-side analysts expect that McKesson Corporation will post 32.77 EPS for the current year.

McKesson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Monday, March 2nd. McKesson’s dividend payout ratio (DPR) is currently 9.43%.

Insider Buying and Selling at McKesson

In other news, EVP Thomas L. Rodgers sold 276 shares of the company’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $816.18, for a total transaction of $225,265.68. Following the transaction, the executive vice president owned 2,268 shares in the company, valued at $1,851,096.24. This represents a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.08% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on MCK. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of McKesson in a research note on Wednesday, December 10th. Robert W. Baird set a $968.00 price objective on shares of McKesson in a research note on Wednesday, January 14th. TD Cowen lifted their price objective on shares of McKesson from $1,000.00 to $1,012.00 and gave the company a “buy” rating in a report on Thursday. Barclays assumed coverage on McKesson in a report on Monday, December 8th. They set an “overweight” rating and a $960.00 target price for the company. Finally, Wall Street Zen cut McKesson from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $918.93.

Key Stories Impacting McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Q3 earnings beat and revenue growth — McKesson reported quarterly EPS above consensus and revenue up ~11.4% year‑over‑year, driven by higher gross profit and operating profit expansion. Business Wire: Q3 Results & Guidance
• Positive Sentiment: Raised FY‑2026 adjusted EPS guidance — Management increased full‑year adjusted EPS to $38.80–$39.20, signaling confidence in specialty drug and oncology/biopharma services growth that underpins margin outlook. Reuters: Boosts 2026 Profit Forecast
• Positive Sentiment: Market reaction — Street enthusiasm around the beat + guidance lift sent shares to multi‑year/all‑time highs and a strong intraday jump as analysts and investors re‑rate growth expectations. Investing.com: Stock Hits All‑Time High
• Neutral Sentiment: Analyst actions mixed — Some firms nudged price targets higher (Wells Fargo, Mizuho) but maintained neutral/equal‑weight stances, so analyst moves are not uniformly bullish. Zacks: Broker View on MCK
• Negative Sentiment: Operational cash‑flow weakness and balance‑sheet items — reporting flagged weaker operating cash flow versus last year and higher total liabilities, which could temper valuation upside if cash conversion doesn’t improve. Insider selling was also noted. QuiverQuant: EPS Beat but Weak Cash Flow

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.